Sagimet Biosciences Inc. (SGMT) stock
SGMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.22−0.71 (-6.50%)
Close on Nov 13, 2026Market cap $635.26MP/E –Yield –
Sagimet Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Sagimet Biosciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $41.60M, down 10.6% year over year. For fiscal 2025 it was $39.05M, up 1.6% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.05M | +1.6% |
| FY2024 | Dec 31, 2024 | $38.44M | +94.4% |
| FY2023 | Dec 31, 2023 | $19.78M | -20.6% |
| FY2022 | Dec 31, 2022 | $24.92M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $16.34M | +67.9% |
| Q2 FY2026 | Jun 30, 2026 | $11.54M | +59.1% |
| Q1 FY2026 | Mar 31, 2026 | $7.00M | -54.4% |
| Q4 FY2025 | Dec 31, 2025 | $6.73M | -52.6% |
| Q3 FY2025 | Sep 30, 2025 | $9.73M | -23.1% |
| Q2 FY2025 | Jun 30, 2025 | $7.25M | +14.8% |
| Q1 FY2025 | Mar 31, 2025 | $15.34M | +191.6% |
| Q4 FY2024 | Dec 31, 2024 | $14.22M | +151.3% |
| Q3 FY2024 | Sep 30, 2024 | $12.65M | +155.2% |
| Q2 FY2024 | Jun 30, 2024 | $6.31M | +35.0% |
| Q1 FY2024 | Mar 31, 2024 | $5.26M | +17.3% |
| Q4 FY2023 | Dec 31, 2023 | $5.66M | -3.3% |
| Q3 FY2023 | Sep 30, 2023 | $4.96M | -27.5% |
| Q2 FY2023 | Jun 30, 2023 | $4.68M | -26.6% |
| Q1 FY2023 | Mar 31, 2023 | $4.49M | – |
| Q4 FY2022 | Dec 31, 2022 | $5.85M | – |
| Q3 FY2022 | Sep 30, 2022 | $6.84M | – |
| Q2 FY2022 | Jun 30, 2022 | $6.37M | – |
See a number that looks wrong?